A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive ...

Metformin, a widely used and affordable diabetes drug, could prevent a form of acute myeloid leukemia in people at high risk ...

Promising Cell Therapy Offers Hope for Relapsed or ... team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the ...

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains ...

Our aim is to provide patients access to advanced treatment options while getting the best cancer care. In Acute Myeloid Leukemia (AML), the bone marrow makes abnormal myeloblasts (a type of white ...

Family and friends of Rachel Simon of Hazlet are staging events to find a bone marrow donor who can help her fight off ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Research from the University of Cambridge shows that metformin, a widely used and affordable diabetes drug, could prevent a ...

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the ...